Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 7/20 | 0.36 |
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 0.36 |
| ▸ | SLC6A3 known ✓ | Q01959 | 6/20 | 0.36 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.35 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | GPR6 | P46095 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1833471 | 1.00 | L3MBTL1 (0.41) | L3MBTL1CES2CES1TP53SLC6A4 | |
| SCHEMBL8071415 | 0.98 | L3MBTL1 (0.42) | L3MBTL1CES2CES1TP53SLC6A4 | |
| SCHEMBL30640891 | 0.98 | L3MBTL1 (0.42) | L3MBTL1CES2CES1TP53SLC6A4 | |
| SCHEMBL4718081 | 0.98 | L3MBTL1 (0.42) | L3MBTL1CES2CES1TP53SLC6A4 | |
| SCHEMBL1833474 | 0.98 | L3MBTL1 (0.42) | L3MBTL1CES2CES1TP53SLC6A4 | |
| SCHEMBL8337674 | 0.82 | L3MBTL1 (0.41) | L3MBTL1CES2CES1 | |
| SCHEMBL28026688 | 0.81 | L3MBTL1 (0.50) | L3MBTL1CES2CES1KCNH2ACKR3 | |
| SCHEMBL13390925 | 0.79 | ACKR3 (0.48) | L3MBTL1CES2CES1ACKR3 | |
| SCHEMBL14542094 | 0.79 | L3MBTL1 (0.40) | L3MBTL1CES2CES1TP53KCNH2 | |
| SCHEMBL5021047 | 0.79 | ACKR3 (0.48) | L3MBTL1CES2CES1ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106831742-B | A kind of preparation method of Iloperidone intermediate | 北京医药集团有限责任公司 | 2019-08-23 | — | — | CN | claimed |
| CN-106831742-A | A kind of preparation method of Iloperidone intermediate | 北京医药集团有限责任公司 | 2017-06-13 | — | — | CN | claimed |
| CN-106831742-B | A kind of preparation method of Iloperidone intermediate | 北京医药集团有限责任公司 | 2019-08-23 | — | — | CN | disclosed |
| CN-106831742-B | A kind of preparation method of Iloperidone intermediate | 北京医药集团有限责任公司 | 2019-08-23 | — | — | CN | disclosed |
| US-20180273476-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | MERCK PATENT GMBH (DE) | 2018-09-27 | — | — | US | disclosed |
| US-9914702-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2018-03-13 | — | — | US | disclosed |
| EP-2709985-B1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | BIONOMICS LTD (AU) | 2017-10-04 | — | — | EP | disclosed |
| CN-106831742-A | A kind of preparation method of Iloperidone intermediate | 北京医药集团有限责任公司 | 2017-06-13 | — | — | CN | disclosed |
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | BIONOMICS, LTD (AU) | 2017-03-30 | — | — | US | disclosed |
| US-9493451-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2016-11-15 | — | — | US | disclosed |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | BIONOMICS LIMITED (AU) | 2015-10-22 | — | — | US | disclosed |
| EP-1551831-A1 | METHOD FOR PREPARING RISPERIDONE | Hanmi Pharm. Co., Ltd. (KR) | 2005-07-13 | — | — | EP | disclosed |
| US-20050004141-A1 | Process for the preparation of 3-{2-'4- (6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl!ethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido'1,2-methyl-4h-pyrido',2-a!pyrimidin-4-one | EGIS GYOGYSZERGYAR RT. (HU) | 2005-01-06 | — | — | US | disclosed |
| EP-1461338-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 3-(2-'4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL/ETHYL)-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO'1,2-A/PYRIMIDIN-4-ONE | Egis Gyogyszergyar Rt. (HU) | 2004-09-29 | — | — | EP | disclosed |
| WO-2004035573-A1 | METHOD FOR PREPARING RISPERIDONE | HANMI PHARM. CO., LTD. (KR) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035573-A1 | METHOD FOR PREPARING RISPERIDONE | HANMI PHARM. CO., LTD. (KR) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004009591-A1 | A PROCESS FOR THE PREPARATION OF ANTIPSYCHOTIC RISPERIDONE | AUROBINDO PHARMA LTD. (IN) | 2004-01-29 | — | — | WO | disclosed |
| WO-2003042212-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 3-{2-[4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL]ETHYL}-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE | EGIS Gyógyszergyár Rt. (HU) | 2003-05-22 | — | — | WO | disclosed |
| US-5134147-A | Antipsychotic agents | ADIR ET COMPAGNIE (FR) | 1992-07-28 | — | — | US | disclosed |
| US-5100902-A | Dopamine and Serotonin Antagonists, Antipsychotic Agents | ADIR ET COMPAGNIE (FR) | 1992-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | KCNA3, KCNH3, KCNK3 | SLC6A4 762/4885SLC6A2 478/4885SLC6A3 296/4885 |
| US-20050004141-A1 | Process for the preparation of 3-{2-'4- (6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl!ethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido'1,2-methyl-4h-pyrido',2-a!pyrimidin-4-one | PAH, CYP2F1, CYP2C9 | SLC6A4 1925/4885SLC6A2 3466/4885SLC6A3 3063/4885 |
| US-20180273476-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | KCNA3, KCNH3, KCNK3 | SLC6A4 762/4885SLC6A2 478/4885SLC6A3 296/4885 |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | KCNA3, KCNH3, KCNK3 | SLC6A4 762/4885SLC6A2 478/4885SLC6A3 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.